# Diabetes Research Hub — Monitor Report

**Run date:** 2026-05-05
**Run type:** Scheduled automated review (read-only — no files modified)
**Workspace:** Diabetes_Research

---

## File System Status

All core monitoring outputs are present and current.

| File | Last modified | Age | Status |
|---|---|---|---|
| hub_monitor_report.md | 2026-05-05 | <1 d | OK |
| clinical_trials_latest.json | 2026-05-05 | <1 d | OK |
| pubmed_recent_latest.json | 2026-05-05 | <1 d | OK |
| clinical_trials_summary.md | 2026-05-05 | <1 d | OK |
| pubmed_recent_summary.md | 2026-05-05 | <1 d | OK |
| literature_gap_report.md | 2026-05-04 | 1 d | OK |
| literature_gap_data.json | 2026-04-20 | **14.7 d** | **STALE — re-run gap analysis** |
| agent_state.json | 2026-05-04 | 1 d | OK |
| citation_validation.json | 2026-05-04 | 1 d | OK |
| evidence_network.json | 2026-05-04 | 1 d | OK |
| pmid_verification.json | 2026-05-04 | 1 d | OK |

The hub_monitor.py scan flags 561 result files as older than 14 days (mostly the dated daily snapshots that are intentionally archival). The only working artifact that crosses the 14-day threshold is `literature_gap_data.json`.

Hub_monitor.py reports for today's scan (vs. 2026-05-04):
- 4 new files (today's daily snapshots and yesterday's monitor report)
- 31 modified files (dashboards rebuilt, agent state refreshed, latest snapshots replaced)
- 0 removed files
- 793 total files tracked

---

## Clinical Trial Changes

**Source:** clinical_trials_latest.json (783 trials; ClinicalTrials.gov API v2, 2026-05-05 07:05 UTC).

**Category counts (unchanged from yesterday):**
- T1D Cure & Cell Therapy: 151
- T1D Immunotherapy & Prevention: 71
- T2D Novel Therapies (Phase 2-3): 139
- Diabetes Technology (Devices): 222
- Diabetes Recently Completed with Results: 272

### 1-day diff (2026-05-04 → 2026-05-05)

5 new trials, 0 removed, 0 status changes, 0 newly posted results.

- **NCT07564414** (PHASE 3, NOT_YET_RECRUITING) — *CagriSema vs. Semaglutide head-to-head* — Novo Nordisk A/S. Highest-priority addition; expands Novo's CagriSema phase-3 program against semaglutide as comparator.
- **NCT07563699** (PHASE 1/2, NOT_YET_RECRUITING) — *Semaglutide Depot in T2D* — Mapi Pharma Ltd. Long-acting depot formulation of semaglutide.
- **NCT07564752** (RECRUITING, T1D Cure & Cell Therapy) — Glycemic-control effects on HDL composition/function — CHU Dijon.
- **NCT03940209** (PHASE 2, COMPLETED with results) — Addressing basic needs to improve diabetes outcomes in Medicaid beneficiaries — Washington University. Health-equity intervention; aligns with Tier 1 Health Equity work.
- **NCT04557228** (COMPLETED with results) — ADAM17 and vascular function in diabetes — University of Missouri.

### 7-day diff (2026-04-28 → 2026-05-05)

12 new trials, 3 status changes, 0 new results posted.

Notable status transitions in the past week:
- **NCT07355270** moved NOT_YET_RECRUITING → RECRUITING — radiofrequency vapor ablation pilot.
- **NCT07321678** moved RECRUITING → ACTIVE_NOT_RECRUITING — ASC30 tablets in T2D (enrollment closed).
- **NCT07422831** moved NOT_YET_RECRUITING → ENROLLING_BY_INVITATION — non-prescription glucose sensor pilot.

### Key Phase-3 trials to keep watching

- **VX-880 (zimislecel)** — Vertex stem-cell-derived islet therapy; pivotal Phase 3 NCT06832410 RECRUITING. Companion trial NCT04786262 also Phase 3 RECRUITING. Sister candidate **VX-264** (encapsulated, NCT05791201) ACTIVE_NOT_RECRUITING.
- **Baricitinib (Eli Lilly)** — Two new Phase-3-stage T1D programs in RECRUITING status: NCT07222137 (delay of stage 3 in adults) and NCT07222332 (preserve beta-cell function in pediatrics).
- **Teplizumab Phase 3** — NCT07088068 RECRUITING (placebo-controlled).
- **Diamyd (NCT05018585)** — PHASE 3 RECRUITING; insulin-preservation in T1D.
- **Tirzepatide in T1D** — NCT07284511 (PHASE 2/3, RECRUITING) and the active Lilly companion trials NCT06914895 / NCT06962280.
- **Insulin icodec (NCT07076199)** — PHASE 3 RECRUITING for HbA1c-lowering in T2D; companion trial NCT05823948 just completed with results in past 7 days (not yet posted to results database).
- **Retatrutide** — NCT06260722 vs. semaglutide and NCT05929079 monotherapy both ACTIVE_NOT_RECRUITING.

273 trials in the dataset have results posted. None are new in the past 7 days.

---

## PubMed Highlights

**Source:** pubmed_recent_latest.json (146 unique papers across 16 alert domains; 30-day lookback; 2026-05-05 07:05 UTC).

Papers per domain are evenly distributed at 2 each (baseline alert volume). Volume vs. 7 days ago: 146 unique today vs. 155 on 2026-04-28; 109 papers are new since the 04-28 snapshot.

### Cross-domain papers (highest priority — 9 total)

These appear in 2+ alert domains and are the most actionable signals:

1. **PMID 42051156** — *Considerations for the clinical use of teplizumab in stage 2 Type 1 diabetes: A Consensus Statement from the British Society* (Diabetic Medicine). Domains: T1D Immunotherapy + Key Therapy: teplizumab. **Highest priority — clinical practice consensus directly relevant to Tier 1 Clinical Trial Intelligence.**
2. **PMID 42082522** — *Sex-specific microbial and tryptophan signatures of depression implicate archaeal methanogens and indole-3-acetic acid*. Domains: Diabetes AI/ML + Diabetes Microbiome. Cross-cuts two Tier 1/2 areas.
3. **PMID 42076618** — *A Novel Convolutional Neural Network for Explainable Diabetic Retinopathy Detection and Grade Identification*. Domains: Diabetes AI/ML + Diabetes Complications.
4. **PMID 42078397** — *A loss-of-function variant in [gene]*. Domains: T2D Remission + Diabetes Gene Therapy.
5. **PMID 42074825** — *Renal Fat Fraction and Early Biomarkers of Kidney Injury in T2D*. Domains: T2D GLP-1 New + Diabetes Biomarker.
6. **PMID 42070230** — *Viscous DES-AAV-Foxo1 Delivery System for Corneal Endothelial Dysfunction*. Domains: Diabetes Gene Therapy + Diabetes Multi-Omics.
7. **PMID 42063171** — *miR-103a-3p contributes to diabetic retinopathy progression via suppressing MFN2*. Domains: T2D Remission + Diabetes Complications.
8. **PMID 42046753** — *Effect of breaking up sitting on glucose management* (closed-loop monitoring + immunotherapy populations).
9. **PMID 42034968** — *Bone marrow-derived cells in experimental autoimmune T1D*. Domains: T1D Stem Cell Cure + T1D Immunotherapy.

### Key-therapy mentions (past 30 days)

| Therapy | Paper count | Notable |
|---|---|---|
| dapagliflozin | 5 | High background activity (24 total mentions across 5 papers) |
| orforglipron | 4 | Includes PK bioequivalence (PMID 41994902), cardiometabolic profile vs. SC GLP-1 (PMID 41992023), and a methodological critique (PMID 41984238). |
| icodec | 3 | Cost-utility study in China (PMID 41705603) and once-weekly efsitora alfa review (PMID 42048049). |
| teplizumab | 3 | British consensus statement + two real-world evaluations (Diabetologia, DOM). |
| baricitinib | 2 | Includes islet-tolerance conditioning paper (PMID 42013280, JCI Insight). |
| retatrutide | 2 | Adipose-brain axis review and GIPR:GCGR co-agonism in obese rodents. |
| zimislecel | 0 | No PubMed mentions — but Vertex VX-880 Phase 3 is enrolling (see Trial section). |
| CagriSema | 0 | No PubMed mentions; new Novo trial NCT07564414 added today. |

---

## Gap Analysis Summary

**Source:** literature_gap_report.md (2026-05-04) and literature_gap_data.json (2026-04-20). Gap data is 14.7 days old — recommend a re-run.

### Top 5 ranked gaps (highest gap scores)

All five score 100.0 with 0–1 joint publications:

1. **Beta Cell Regen × Health Equity** — expected ~1,615 joint papers based on geometric mean. Equity analysis of regenerative cell therapies is essentially absent.
2. **Insulin Resistance × Islet Transplant** — 1 joint paper vs. expected ~2,138. IR in transplant recipients affects graft survival but is barely studied.
3. **Islet Transplant × Drug Repurposing** — 0 joint papers. Existing immunosuppressants and metabolic agents have not been computationally screened for islet-protective repurposing.
4. **Islet Transplant × Health Equity** — 0 joint papers. Access disparity for a center-restricted therapy is unstudied.
5. **Gene Therapy × LADA** — 0 joint papers. LADA's autoimmune mechanism is a plausible gene-therapy target with no crossover literature.

### Alignment with our Tier 1 contribution areas

All five top gaps map directly onto Tier 1 capabilities defined in RESEARCH_DOCTRINE.md:

- **Drug Repurposing Computational Screening (Tier 1, Score 18/20)** — directly addresses gap #3 (Islet Transplant × Drug Repurposing).
- **Literature Synthesis & Gap Analysis (Tier 1, Score 19/20)** — gaps #1, #4, and the broader Health Equity intersections are exactly the cross-domain syntheses our doctrine designates as "no one is systematically synthesizing across all 35 domains."
- **Epidemiological Data Analysis / Health Equity (Tier 1, Score 17/20)** — gaps #1 and #4 (both Health Equity crossings) align with our "quantify disparity" mandate.
- **Multi-Omics Biomarker Integration (Tier 1, Score 19/20)** — gap #2 (IR × Islet Transplant) is amenable to biomarker-based recipient stratification.

The Beta Cell Regen × Health Equity gap (#1) and the two Islet Transplant cross-cuts (#3, #4) are the strongest immediate computational-contribution candidates. All gap classifications remain at BRONZE evidence level pending domain-expert review per the Research Doctrine.

---

## Breaking News (web check)

Two genuinely significant items in the last ~7 days; the rest is recap of earlier-April activity.

- **2026-04-28 — Boehringer Ingelheim SYNCHRONIZE-1 Phase 3 (survodutide).** Met co-primary endpoints; up to 16.6% sustained weight loss at 76 weeks vs. 3.2% placebo. This is a Phase-3 readout and warrants tracker entry.
- **2026-04-22 — Sanofi/Tzield (teplizumab) FDA action.** Approved in the US to delay onset of stage 3 T1D in young children (label expansion). Aligns with PubMed PMID 42051156 (British consensus on stage-2 use) and ongoing Phase-3 NCT07088068.

Earlier-April items already in our dataset (no action needed): orforglipron (Foundayo) FDA approval on 2026-04-01 — fastest NME approval since 2002; first generic dapagliflozin tablets approved 2026-04-07.

---

## Recommended Actions

Ordered by priority. Items 1 and 2 are time-sensitive.

1. **Run: `python project1_literature_gap_analysis.py`** — `literature_gap_data.json` is 14.7 days old. Re-run before citing the top-5 list externally.
2. **Update Diabetes_Research_Tracker.xlsx** with three trials added/changed today:
   - Add **NCT07564414** (Novo CagriSema vs. Semaglutide, Phase 3, NOT_YET_RECRUITING).
   - Add **NCT07563699** (Mapi Pharma semaglutide depot, Phase 1/2).
   - Update status for **NCT07321678** (RECRUITING → ACTIVE_NOT_RECRUITING) and **NCT07355270** (NOT_YET → RECRUITING).
3. **Add SYNCHRONIZE-1 (survodutide) Phase-3 readout** to the tracker as an external Phase-3 result not currently in the ClinicalTrials.gov pull (BI press release, 2026-04-28). Evidence level: BRONZE pending the corresponding peer-reviewed paper.
4. **Review cross-domain paper PMID 42051156** (teplizumab British consensus) — relevant to T1D Immunotherapy + Clinical Trial Intelligence (Tier 1). Likely candidate for inclusion in the next research-findings update.
5. **Initiate Tier 1 contribution work on Islet Transplant × Drug Repurposing** (gap #3) — zero joint publications, full alignment with Tier 1 score-18 area, computational screen feasible with existing OpenTargets / DrugBank access.
6. **No action required** for: hub_monitor scan, daily clinical-trial pull, daily PubMed pull, dashboards (all refreshed within the last 24 h).

---

*Generated by automated monitor task — read-only run. Evidence-level annotations follow Research Doctrine v1.0; new gap claims marked BRONZE pending expert validation.*
